Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, \>/= 18 years of age~* Treatment with Pegasys according to label and standard clinical practice~* HBeAg negative serologically proven chronic hepatitis B with or without cirrhosis~* Serum alanine aminotransferase (ALT) \> upper limit of normal (ULN) but \</= 10 x ULN~* Hepatitis B Virus (HBV) DNA \>/= 2000 IU/mL~Exclusion Criteria:~* Contraindications to Pegasys as detailed in the label~* Co-infection with hepatitis A, hepatitis C or HIV~* Pregnant or lactating women~* Participants should not receive concomitant therapy with telbivudine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic Hepatitis B Participants (Type: None): Hepatitis B e antigen (HBeAg) chronic hepatitis B (CHB) participants who received treatment with pegylated interferon alfa (peginterferon alfa) according to China labeling and China standard of care and were followed up to 1 year after treatment cessation.

Based on this trial design, predict the completion outcome and termination type (if applicable).